Ashutosh Wechalekar

27.0k total citations · 2 hit papers
267 papers, 10.5k citations indexed

About

Ashutosh Wechalekar is a scholar working on Molecular Biology, Nephrology and Genetics. According to data from OpenAlex, Ashutosh Wechalekar has authored 267 papers receiving a total of 10.5k indexed citations (citations by other indexed papers that have themselves been cited), including 248 papers in Molecular Biology, 83 papers in Nephrology and 63 papers in Genetics. Recurrent topics in Ashutosh Wechalekar's work include Amyloidosis: Diagnosis, Treatment, Outcomes (240 papers), Parathyroid Disorders and Treatments (73 papers) and Neuroendocrine Tumor Research Advances (40 papers). Ashutosh Wechalekar is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (240 papers), Parathyroid Disorders and Treatments (73 papers) and Neuroendocrine Tumor Research Advances (40 papers). Ashutosh Wechalekar collaborates with scholars based in United Kingdom, United States and Italy. Ashutosh Wechalekar's co-authors include Philip N. Hawkins, Julian D. Gillmore, Helen J. Lachmann, Carol Whelan, Giampaolo Merlini, Giovanni Palladini, Janet A. Gilbertson, Dorota Rowczenio, Marianna Fontana and Simon Gibbs and has published in prestigious journals such as The Lancet, Circulation and Journal of Clinical Oncology.

In The Last Decade

Ashutosh Wechalekar

248 papers receiving 10.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

2012 625 citations Giovanni Palladini, Morie A. Gertz et al. profile →
Systemic amyloidosis

2015 621 citations Ashutosh Wechalekar, Julian D. Gillmore et al. profile →

Peers

Countries citing papers authored by Ashutosh Wechalekar

Since Specialization

Citations

This map shows the geographic impact of Ashutosh Wechalekar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashutosh Wechalekar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashutosh Wechalekar more than expected).

Fields of papers citing papers by Ashutosh Wechalekar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashutosh Wechalekar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashutosh Wechalekar. The network helps show where Ashutosh Wechalekar may publish in the future.

Co-authorship network of co-authors of Ashutosh Wechalekar

This figure shows the co-authorship network connecting the top 25 collaborators of Ashutosh Wechalekar. A scholar is included among the top collaborators of Ashutosh Wechalekar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashutosh Wechalekar. Ashutosh Wechalekar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Outcomes of daratumumab–bortezomib–thalidomide–dexamethasone in treatment‐naive systemic AL amyloidosis 2025 ·British Journal of Haematology ·Jahanzaib Khwaja, Sriram Ravichandran, Oliver C. Cohen, Darren Foard, (unknown), Ana Martinez–Naharro, Lucia Venneri, Marianna Fontana, Philip N. Hawkins, Julian D. Gillmore, Helen J. Lachmann, Carol Whelan, Shameem Mahmood, Ashutosh Wechalekar	1
2	Defining a New “Mayo Stage IIIc” Ultra Poor Risk Category in Systemic AL Amyloidosis: Incorporating Echocardiographic Global Longitudinal Strain to the European Modified Mayo Staging System 2024 ·Blood ·Jahanzaib Khwaja, Sriram Ravichandran, (unknown), Oliver C. Cohen, Darren Foard, Ana Martinez–Naharro, Lucia Venneri, Marianna Fontana, Carol Whelan, Philip N. Hawkins, Julian D. Gillmore, Helen J. Lachmann, Shameem Mahmood, Amy A. Kirkwood, Ashutosh Wechalekar	0
3	Prognostication in IgM and Lymphoplasmacytic Lymphoma Associated Systemic AL Amyloidosis 2024 ·Blood ·Jahanzaib Khwaja, Sriram Ravichandran, Darren Foard, Ana Martinez–Naharro, Lucia Venneri, Marianna Fontana, Carol Whelan, Philip N. Hawkins, Julian D. Gillmore, Helen J. Lachmann, Shameem Mahmood, (unknown), Ashutosh Wechalekar	0
4	5 Cardiovascular magnetic resonance (CMR) in transthyretin amyloid cardiomyopathy – a study of natural history and treatment repsonse 2024 ·Abstracts ·Rishi Patel, Ana Martinez–Naharro, Yousuf Razvi, Adam Ioannou, Aldostefano Porcari, Liza Chacko, James Brown, Daniel Knight, Tushar Kotecha, Charlotte Manisty, James Moon, Helen J. Lachmann, Ashutosh Wechalekar, Carol Whelan, Lucia Venneri, Peter Kellman, Philip N. Hawkins, Julian D. Gillmore, Marianna Fontana	1
5	Clinical and clonal characteristics of monoclonal immunoglobulin M‐associated type I cryoglobulinaemia 2023 ·British Journal of Haematology ·Jahanzaib Khwaja, Josephine M. I. Vos, (unknown), (unknown), (unknown), (unknown), Arjan J. Kwakernaak, Rajeev Gupta, Ali Rismani, Charalampia Kyriakou, Ashutosh Wechalekar, Shirley D’Sa	9
6	Limited Utility of Mayo 2012 Cardiac Staging System for Risk Stratification of Patients with Advanced Cardiac AL Amyloidosis - Analysis of a Uniformly Treated Cohort of 1275 Patients 2023 ·Blood ·Jahanzaib Khwaja, Sriram Ravichandran, (unknown), Oliver Cohen, Darren Foard, (unknown), Lucia Venneri, Marianna Fontana, Philip N. Hawkins, Julian D. Gillmore, Helen J. Lachmann, Shameem Mahmood, Carol Whelan, Ashutosh Wechalekar	5
7	Linking changes in quality of life to haematologic response and survival in systemic immunoglobulin light‐chain amyloidosis 2023 ·British Journal of Haematology ·Oliver Cohen, Regina Rendas‐Baum, Kristen McCausland, Darren Foard, Richa Manwani, Sriram Ravichandran, Helen J. Lachmann, Shameem Mahmood, Brendan Wisniowski, Philip N. Hawkins, Julian D. Gillmore, (unknown), Sabrina Rebello, Ashutosh Wechalekar	3
8	Pooled Analysis of Safety from Birtamimab Phase 1-3 Studies in Patients with Light Chain (AL) Amyloidosis 2023 ·Blood ·Vaishali Sanchorawala, Ashutosh Wechalekar, Efstathios Kastritis, Giovanni Palladini, Stefan Schönland, Raymond L. Comenzo, Anita D’Souza, Jack Khouri, Víctor H. Jiménez‐Zepeda, (unknown), (unknown), Wenying Huang, (unknown), Morie A. Gertz	2
9	Tracking multi-organ treatment response in systemic AL amyloidosis with cardiac magnetic resonance derived extracellular volume mapping 2023 ·European Heart Journal - Cardiovascular Imaging ·Adam Ioannou, (unknown), Yousuf Razvi, (unknown), Aldostefano Porcari, Lucia Venneri, David F. Hutt, Helen J. Lachmann, Ashutosh Wechalekar, Philip N. Hawkins, (unknown), Marianna Fontana	1
10	Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy 2021 ·Heart ·Steven Law, Aviva Petrie, Liza Chacko, Oliver Cohen, Sriram Ravichandran, Janet A. Gilbertson, Dorota Rowczenio, Ashutosh Wechalekar, Ana Martinez–Naharro, Helen J. Lachmann, Carol Whelan, David F. Hutt, Philip N. Hawkins, Marianna Fontana, Julian D. Gillmore	20
11	99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis 2021 ·European Heart Journal - Cardiovascular Imaging ·Candida Cristina Quarta, (unknown), David F. Hutt, (unknown), Richa Manwani, Sajitha Sachchithanantham, Shameem Mahmood, Carol Whelan, Marianna Fontana, Ana Martinez–Naharro, Liza Chacko, Helen J. Lachmann, Julian D. Gillmore, Claudio Rapezzi, Philip N. Hawkins, Ashutosh Wechalekar	42
12	Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light‐chain amyloidosis 2020 ·British Journal of Haematology ·Oliver C. Cohen, Faye Sharpley, Julian D. Gillmore, Helen J. Lachmann, Sajitha Sachchithanantham, Shameem Mahmood, Marianna Fontana, Carol Whelan, Ana Martinez–Naharro, Charalampia Kyriakou, Neil Rabin, Rakesh Popat, Kwee Yong, (unknown), (unknown), Philip N. Hawkins, Ashutosh Wechalekar	28
13	Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy 2019 ·British Journal of Haematology ·Richa Manwani, Shameem Mahmood, Sajitha Sachchithanantham, Helen J. Lachmann, Julian D. Gillmore, Kwee Yong, Neil Rabin, Rakesh Popat, Charalampia Kyriakou, (unknown), Faye Sharpley, Mark Smith, (unknown), (unknown), Philip N. Hawkins, Ashutosh Wechalekar	36
14	Bioimpedance vector analysis for the detection of extracellular volume overload and sarcopenia in systemic AL amyloidosis 2018 ·British Journal of Haematology ·Tamer Rezk, Andrew Davenport, (unknown), Helen J. Lachmann, Marianna Fontana, Ana Martinez–Naharro, Sajitha Sachchithanantham, (unknown), Shameem Mahmood, Aviva Petrie, Carol Whelan, Jennifer H. Pinney, Darren Foard, Thirusha Lane, Taryn Youngstein, Ashutosh Wechalekar, Philip N. Hawkins, Julian D. Gillmore	4
15	Successful treatment of systemic AA amyloidosis associated with underlying Hodgkin lymphoma 2018 ·British Journal of Haematology ·Richa Manwani, David Wrench, Ashutosh Wechalekar, Helen J. Lachmann	2
16	Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis 2018 ·British Journal of Haematology ·Faye Sharpley, Richa Manwani, Shameem Mahmood, Sajitha Sachchithanantham, Helen J. Lachmann, (unknown), Carol Whelan, Philip N. Hawkins, Ashutosh Wechalekar	12
17	Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis 2017 ·British Journal of Haematology ·Tamer Rezk, Carol Whelan, Helen J. Lachmann, Marianna Fontana, Sajitha Sachchithanantham, Shameem Mahmood, Fakhar Z. Khan, Raj Khiani, Joseph Tomson, Taryn Youngstein, Julian D. Gillmore, Philip N. Hawkins, Ashutosh Wechalekar	17
18	Prolonged Progression Free Survival and Time to Next Treatment Are Achievable Outcomes in Patients with Systemic AL Amyloidosis Treated with Novel Agent Chemotherapy: Analysis of the Alchemy Study 2017 ·Blood ·Richa Manwani, Darren Foard, Shameem Mahmood, Sajitha Sachchithanantham, Marianna Fontana, Carol Whelan, Candida Cristina Quarta, Thirusha Lane, Helen J. Lachmann, Julian D. Gillmore, Philip N. Hawkins, Ashutosh Wechalekar	1
19	Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature. 2016 ·PubMed ·Thirusha Lane, Julian D. Gillmore, Ashutosh Wechalekar, Philip N. Hawkins, Helen J. Lachmann	37
20	Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival 2012 ·Blood ·Christopher P. Venner, Thirusha Lane, Darren Foard, Lisa Rannigan, Simon Gibbs, Jennifer H. Pinney, Carol Whelan, Helen J. Lachmann, Julian D. Gillmore, Philip N. Hawkins, Ashutosh Wechalekar	197

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact